Drug Search Results
More Filters [+]

PBF-680

Alternative Names: pbf-680, pbf680, pbf 680
Latest Update: 2024-04-19
Latest Update Note: Clinical Trial Update

Product Description

Adenosine A1 Antagonist for Asthma and COPD (Sourced from: https://www.palobiofarma.com/pipeline-2/)

Mechanisms of Action: ADORA1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Palobiofarma SL
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PBF-680

Countries in Clinic: Spain

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Asthma|Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Respire

P2

Completed

Chronic Obstructive Pulmonary Disease

2024-02-27

35%

2021-001732-25

P2

Active, not recruiting

Chronic Obstructive Pulmonary Disease

2023-01-07

2017-003663-35

P2

Active, not recruiting

Asthma

2019-02-14

Recent News Events